According to the CDC, colorectal cancer is the second leading cancer killer in the United States and third most commonly diagnosed cancer in the world. GLOBOCAN estimated that, in 2008, 1.23 million new cases of colorectal cancer were clinically diagnosed, with a total of more than 600,000 worldwide deaths.
Currently, screening for colorectal cancer is performed by fecal blood testing, which is ineffective and endoscopic methods which are very expensive. There is no predictive diagnostic technology available for a simple blood or stool test to identify colon cancer sensitively and specifically before symptoms appear.
The agreement with SYSU forms the second hub in the Center for Sustainable Health's Global Biosignatures Network (GBN) - an effort to harness scientific, academic, industry, and healthcare system resources to make a major impact on 21st century healthcare practice. SYSU joins founding member Chang Gung University, which focuses on biomarker discovery and validation for oral and colorectal cancer.
Dr. Michael Birt, director of Center for Sustainable Health at ASU's Biodesign Institute states, "The overarching goal of the Global Biosignatures Network is to develop a broad spectrum of skills to transform medicine in health systems over the next decade through strategic alliances. In particular, GBN seeks to build expertise in health economics, disease modeling, clinical research and trial design, care delivery, regulatory affairs, bioinformatics, information technologies, and overall technical expertise. By establishing Biosignatures Centers, we hope
|Contact: Joe Caspermeyer|
Arizona State University